Milliman MedInsight Achieves ONC Certification to Advance Value-Based Care in Healthcare Analytics
- Milliman MedInsight's ONC certification validates its eCQM solutions, enhancing compliance and patient care for healthcare providers.
- The certification supports Milliman's goal of empowering healthcare entities through improved data integration and actionable insights.
- Milliman's focus on value-based care positions it as a key partner for organizations prioritizing patient outcomes and care quality.
Milliman MedInsight Elevates Value-Based Care with ONC Certification
Milliman MedInsight, a leading healthcare data and analytics provider, embarks on 2026 with a renewed commitment to value-based care following its recent certification from the Office of the National Coordinator for Health Information Technology (ONC). This certification, part of the Health IT Certification Program, confirms that Milliman's electronic Clinical Quality Measures (eCQM) solutions adhere to stringent federal standards for capability, functionality, and security. By achieving this certification, Milliman not only streamlines reporting processes for healthcare providers but also enhances patient care and ensures compliance with critical regulations.
Nicole Zilliox, Director of Clinical Products at Milliman MedInsight, highlights the significance of this achievement, stating that the certification serves as third-party validation of their solutions' effectiveness in supporting healthcare organizations. By enabling accurate reporting of eCQMs and clinical data, Milliman positions itself as a vital partner for healthcare entities striving to meet evolving regulatory standards. This focus on compliance is particularly timely, as healthcare organizations increasingly pivot towards value-based models that prioritize patient outcomes over volume of services rendered.
The ONC certification aligns with Milliman MedInsight's broader vision to empower healthcare providers, payers, and public health agencies through enhanced data integration. The organization seeks to consolidate clinical data from diverse sources, including electronic health records, claims, lab results, and admission/discharge/transfer systems. Rich Moyer, Chief Product Officer, underscores the importance of trusted and timely data in transforming healthcare performance. By leveraging its certification and advanced integration strategies, Milliman aims to assist healthcare organizations in converting data into actionable insights that drive clinical and operational excellence in an ever-evolving healthcare landscape.
In addition to its focus on eCQM reporting, Milliman MedInsight is committed to enhancing care quality and operational efficiency through its data integration capabilities. The emphasis on value-based care reflects a growing trend in the healthcare industry, where organizations are increasingly evaluated on patient outcomes and the quality of care provided. By equipping healthcare professionals with the tools they need to analyze and act on clinical data, Milliman is at the forefront of this transformative movement.
The ONC certification not only reinforces Milliman MedInsight's reputation as a trusted healthcare partner but also positions the company to play a pivotal role in the future of healthcare analytics. As the landscape shifts towards more value-oriented approaches, Milliman's strategic initiatives will likely resonate well with providers seeking to enhance their performance and patient care outcomes.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…